Information Provided By:
Fly News Breaks for July 27, 2016
CHRS
Jul 27, 2016 | 06:30 EDT
Citi analyst Mohit Bansal started Coherus Biosciences with a Buy rating and $36 price target. Neulasta and Humira biosimilar clarity in the next 12 months should provide upside, the analyst contends.
News For CHRS From the Last 2 Days
There are no results for your query CHRS